Clinical Trials Directory

Trials / Completed

CompletedNCT00528268

Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy

Prospective Phase I/II Study to Evaluate Effects of Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
22 (actual)
Sponsor
University of Utah · Academic / Other
Sex
All
Age
1 Day – 6 Months
Healthy volunteers
Not accepted

Summary

In this single-center trial, we will evaluate the effects of NaPB on presymptomatic Spinal Muscular Atrophy (SMA) type I (cohort 1)and presymptomatic SMA type II (cohort 2) infants. A variety of outcome measures will be performed at each study visit to follow the course of the disease. Total duration of the study for type I infants will be 18 months, for type II infants, 24 months.

Detailed description

Perform a phase I/II study to evaluate effects of sodium phenylbutyrate (NaPB) in a cohort of presymptomatic infants, predicted to develop either SMA type 1 or SMA type 2 given genotype and family history of an older sibling with the respective SMA type. Primary outcomes: 1) to collect additional safety and pharmacokinetic data in neonates and young infants administered NaPB within the dosing guidelines already in use for urea cycle disorder therapy, and 2) to determine possible benefit of early treatment intervention with regard to status of denervation and functional motor status at specific time points for which we have matched natural history data to perform a comparison between cohorts and between each cohort and participants from our natural history database matched for age, SMN2 dosage and gender.

Conditions

Interventions

TypeNameDescription
DRUGSodium phenylbutyrateSodium phenylbutyrate is dispensed as a powder, 450-600 mg/kg/day, divided into four doses. For cohort 1, treatment and monitoring continues for 18 months. For cohort 2, treatment and monitoring continues for 24 months.

Timeline

Start date
2007-07-01
Primary completion
2013-12-01
Completion
2013-12-01
First posted
2007-09-12
Last updated
2025-02-28
Results posted
2015-07-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00528268. Inclusion in this directory is not an endorsement.